Role of Mirikizumab in the Treatment of Inflammatory Bowel Disease-From Bench to Bedside.

J Clin Med · 2025 · PMC11818495 · PMID 39941671

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a numerical trendno p-value reported

With regards to CD, the VIVID-1 study suggested that when comparing clinical and endoscopic endpoints, there was a numerical trend towards a greater response with mirikizumab than ustekinumab.

also in 669 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.